



**Office of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**December 9, 2008 6:30 – 9:00 p.m. \*\***

- 1. Executive Session** **6:30 - 7:00**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:25**
  - Clinical Programs Update
  - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:25 - 7:25**
  - No items
- 6. Clinical Update: Drug Reviews** **7:25 – 7:35**

(Public comment prior to Board action)

  - Relestor<sup>®</sup> (methylnaltrexone) injection
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:35 – 8:30**

(Public comment prior to Board action)

  - Acne Drugs: Topical Anti-Infectives
  - Anti-hypertensives: ARB Combinations (Azor<sup>®</sup>)
  - Anti-hypertensives: Renin Inhibitors (Tekturna<sup>®</sup>/Tekturna HCT<sup>®</sup>)
  - Anti-Infectives: Cephalosporins (Suprax<sup>®</sup> tablet)
  - Anti-psychotics: Atypicals and Combinations (Seroquel XR<sup>®</sup>)
  - Mood Stabilizers (Equetro<sup>®</sup>)
  - Ophthalmic Antihistamines
  - Ossification Enhancing Agents (Fortical<sup>®</sup>)
  - Pulmonary: Beta-Agonists: Short Acting Metered Dose Inhalers (Maxair<sup>®</sup> brief review)
  - Pulmonary: Inhaled Glucocorticoids: Single Agent Metered Dose Inhaler (QVAR<sup>®</sup> brief review)
- 8. Drug Classes – Annual Review** **8:30 – 8:35**

(Public comment prior to Board action)

**Class review documents available on OVHA web site 12/09/08 @ 12 Noon**

**Anti-Diabetics**

  - Insulin

- Oral
  - Alpha Glucosidase Inhibitors
  - Biguanides and Combinations
  - Meglitinides
  - Sulfonylureas (Second Generation)
  - Thiazolidinediones and Combinations
  - Dipeptidyl Peptidase Inhibitors and Combinations
- Peptide Hormones

<b>9. RetroDUR</b>	<b>8:35 - 8:45</b>
▪ Chantix <sup>®</sup> and Smoking Cessation Products	
<b>10. New Drug Product Plan Exclusions (Consent Agenda Topic)</b>	<b>8:45 - 8:50</b>
<b>11. Updated New-to-Market Drug Monitoring Log</b>	<b>8:50 - 8:55</b>
<b>12. General Announcements</b>	<b>8:55 - 9:00</b>
Selected FDA Safety Alerts	
▪ Bisphosphonates - atrial fibrillation	
<b>13. Adjourn</b>	<b>9:00</b>